Glaukos Corporation Q3 2025 Financial Results

Glaukos Corporation announced its financial results for the third quarter ended September 30, 2025. The company reported record net sales of $133.5 million, a 38% increase year-over-year. Key highlights include a 45% increase in Glaucoma net sales to $110.2 million and a 57% increase in U.S. Glaucoma net sales to $80.8 million. The company raised its 2025 net sales guidance to $490-$495 million and introduced preliminary 2026 net sales guidance of $600-$620 million. Glaukos continues to advance its pipeline of novel therapies for glaucoma, corneal disorders, and retinal diseases. The company also highlighted the successful launch of iDose TR, a long-duration intracameral procedural pharmaceutical for glaucoma treatment.